RxDoctor Payments Data

Anna Hadid, MD

Internal Medicine · Tampa, FLNPI 1477554137

Payments from drug & device makers

$939in general payments, 2019–2025

Across 62 payments — averaging $15.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$227
  • Pfizer$126
  • Amgen$109
  • Biohaven Pharmaceuticals, Inc.$75
  • Biohaven Pharmaceutical Holding Company Ltd.$58
  • Novo Nordisk$56
  • plus $288 from 12 others

What the payments were for

  • Food & beverage$92599%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$939 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$169,929
Medicare patients
485
Services billed
1,814

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban84$68,891
OzempicSemaglutide28$35,525
Breo ElliptaFluticasone/Vilanterol29$27,192
JardianceEmpagliflozin20$26,406
MyrbetriqMirabegron26$24,945
JanuviaSitagliptin Phosphate21$23,907
XareltoRivaroxaban15$23,568
FarxigaDapagliflozin Propanediol17$21,485
TrulicityDulaglutide20$19,658
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$15,506
Atorvastatin Calcium358$5,058
SynthroidLevothyroxine Sodium54$3,854
Levothyroxine Sodium272$3,479
Rosuvastatin Calcium190$3,466
Losartan Potassium210$2,703

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$126$68,89184 claims
GSKBreo Ellipta, Trelegy Ellipta$17$42,69744 claims
Novo NordiskOzempic$56$35,52528 claims
Boehringer IngelheimJardiance$35$26,40620 claims
Astellas Pharma US IncMyrbetriq$23$24,94526 claims
MerckJanuvia$11$23,90721 claims
Johnson & JohnsonXarelto$15$23,56815 claims
AstraZenecaFarxiga$227$21,48517 claims
Lilly USA, LLCTrulicity$15$19,65820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →